- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
Synonyms: Gazyva, GA101, Gazyvaro, Afutuzumab
Obinutuzumab (anti-CD20) (Gazyva, GA101, Gazyvaro, Afutuzumab) is a novel, type II, glycoengineered, humanized anti-CD20 monoclonal antibody that has been developed for lymphocytic leukemia and lymphoma of B-cell origin. MW : 146.1 kD.
| Name | Citation | CD38 | CD45 | CD39 | CD88 | CD73 | Others |
|---|---|---|---|---|---|---|---|
| RBN013209 | 0 | ||||||
| MK-0159 | 0 | ||||||
| CD38 inhibitor 1 (compound 78c) | 7 | ||||||
| AB680 | 0 | ||||||
| NQ301 | 1 | TXA2 receptor | |||||
| SodiuM Metatungstate | 3 | ||||||
| PMX-53 | 3 | ||||||
| LY-3475070 | 2 |
| Description |
Obinutuzumab (anti-CD20) (Gazyva, GA101, Gazyvaro, Afutuzumab) is a novel, type II, glycoengineered, humanized anti-CD20 monoclonal antibody that has been developed for lymphocytic leukemia and lymphoma of B-cell origin. MW : 146.1 kD.
|
|---|---|
| In vitro |
GA101 is the first Fc-engineered, type II humanized IgG1 antibody against CD20. Relative to rituximab, GA101 has increased direct and immune effector cell-mediated cytotoxicity and exhibits superior activity in cellular assays and whole blood B-cell depletion assays. |
| Cell Research |
Objective: Annexin V/PI FACS assay |
| In vivo |
In human lymphoma xenograft models, GA101 exhibits superior antitumor activity, resulting in the induction of complete tumor remission and increased overall survival. In nonhuman primates, GA101 demonstrates superior B cell–depleting activity in lymphoid tissue, including in lymph nodes and spleen. |
| Animal Research |
Objective: Tumor control ratio (TCR) and tumor growth inhibition (TGI) |
References |
|
| CAS No. | 949142-50-1 |
|---|---|
| Isotype | Human IgG1 isotype control |
| Source | Humanized (from mouse) |
| Sterility | 0.2 μM filtered |
| Formulation | PBS buffer, pH 7.2 |
| Storage (From the date of receipt) |
Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.